Covington-based CTI Clinical Trial and Consulting Services (CTI), has signed a Memorandum of Understanding (MOU) with Samsung Medical Center (SMC), located in Seoul, South Korea.
CTI is a multi-national, privately held, full-service contract research organization
The purpose of the Memorandum is to affirm both CTI’s and SMC’s commitment to identifying and developing opportunities for cooperation and collaboration in advancing clinical research in fields such as rare and orphan disease, regenerative medicine, and hematology/oncology.
The Memorandum was signed by Patrick J. Earley, CTI’s Chief International Business Officer and Ki Woong Sung, Director of Clinical Research Institute at SMC.
“We are thrilled to enter this strategic partnership with Samsung Medical Center,” said Earley. “Samsung Medical Center is an innovative research site that is committed to bringing life-changing drugs to patients in need, just as CTI is. We have been working throughout the Asia-Pacific region for nearly a decade, and we have many successful collaborations throughout the region with leading academic centers and emerging biotechnology companies. CTI continues to grow steadily in the region, and we look forward to future accomplishments/efficiencies enabled by this partnership.”
CTI, with an annual staff retention rate of 95 percent, has been working for two decades in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 30 offices worldwide to serve more than 200 pharmaceutical, biotechnology, and medical device clients.
Bowers, Shapiro added to business development, clinical project management teams
Bowers
CTI has announced the additions of Drs. Brian Bowers and Lisa Shapiro to the Business Development and Clinical Project Management teams, respectively.
Bowers comes to CTI with a strong background in real world evidence/health outcomes and economics research. Prior to joining the CTI team, Brian spent more than 25 years at GlaxoSmithKline working in clinical research, health outcomes and economics research, and medical governance/compliance. Brian earned both his Doctorate and Bachelor of Pharmacy from the University of Georgia.
“We are happy to announce the addition of Brian to the Business Development team,” remarks Matt Hodskins, Senior Director, Business Development & Client Management – RSA/RWE. “He brings with him a wealth of knowledge and experience, and we look forward to all he will accomplish as the newest member of the team.”
Shapiro
Shapiro joins CTI with more than 20 years of experience in clinical research, project management and drug development, and a particularly strong background in oncology and immunology. Prior to joining CTI, Lisa held the roles of Executive Director, Global Drug Development at PRA Health Sciences and Director/Therapeutic Lead, Immunology at Abbvie INC.
She also spent 16 years at Astellas functioning in advancing roles from Sr. CRA through to Director, Clinical Project Management and finally as a Therapeutic Area Lead in Oncology. Lisa earned her PhD in Pharmacy/Neuroscience at the University of Illinois and her MA in Psychology at the University of Texas.
“We are thrilled to welcome Lisa to our team,” comments Dr. Melanie Bruno, Vice President, Global Clinical Project Management. “She has a strong background in some of CTI’s core therapeutic areas, and we look forward to seeing her utilize that expertise to help lead the department to future successes.”
CTI Clinical Trial and Consulting Services
